Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

C’était l’histoire dont tout le monde parlait. En 2024, Novo Nordisk, grâce à ses traitements révolutionnaires contre l’obésité, s’imposait comme la première capitalisation boursière d’Europe, ...

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, ...

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...

"Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs" was originally created and published by Pharmaceutical ...

In a recent SEC filing, it was revealed that David A Ricks, President at Eli Lilly LLY, made a noteworthy insider purchase on August 12,. What Happened: Ricks demonstrated confidence in Eli Lilly by ...

Texas Attorney General Ken Paxton claims that through an alleged kickback scheme Eli Lilly “fraudulently sought to maximize profits at taxpayer expense.” ...

Texas Attorney General Ken Paxton said the state is suing Eli Lilly for allegedly bribing clinicians to prescribe its GLP-1 ...

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...